Abstract Details

Title Mesenchymal Stem Cells (MSCs) Protect Hypoxic Neuronal Cells by Mitochondrial Transfer

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 4-002

Objective In this study we aim to understand the mechanism by which MSCs may transfer mitochondria and protect PC12 cells under in vitro hypoxic condition.

Background Stroke is the second leading cause of death and disability worldwide. Several mechanisms are involved in this pathology, with mitochondria playing a central role. Protecting mitochondrial function after ischemia is considered as an important therapeutic target for post-ischemic neuroprotection. The use of mesenchymal stem cells (MSCs) as a therapeutic modality for stroke is attractive and promising. Intercellular mitochondrial transfer for replacement of impaired mitochondria has emerged as one of the probable mechanisms. The in vitro transfer of mitochondria to different cell lines have been extensively studied and it is suggested that such transfer can restore mitochondrial functioning.

Design/Methods PC12 cells were kept in hypoxic chamber to induce hypoxia. Cells were then co-cultured with bone marrow (BM) MSCs and incubated for 24 hours. Cell survival and mitochondrial transfer were assayed using flow cytometry. Confocal microscopy was used to visualize mitochondrial transfer. qPCR was performed to check for expression of various markers of mitochondrial transfer, biogenesis, fission and fusion.

Results MSCs when co-cultured with PC12 where able to increase the survival of the hypoxic cells. Increase in mitochondrial transfer was observed following co-culturing with hypoxic cells in comparison to normal cells. Confocal microscopy confirmed the transfer of mitochondria following co-culture. Increase in the expression of TFAM, SIRT1, MIRO1, OPA1, FIS and DRP1 was observed by qPCR assay.

Conclusions MSCs increase survival of hypoxic PC12 cells by transferring viable mitochondria.

Authors/Disclosures
Deepaneeta Sarmah, M Pharm (National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A)) PRESENTER	Miss Sarmah has nothing to disclose.
	No disclosure on file
	No disclosure on file
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine)	Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Pallab Bhattacharya, PhD (National Institute of Pharmaceutical Education and Research (NIPER),Ahmedabad.)	Dr. Bhattacharya has nothing to disclose.